207 related articles for article (PubMed ID: 34803378)
1. Effective Triple-Negative Breast Cancer Targeted Treatment Using iRGD-Modified RBC Membrane-Camouflaged Nanoparticles.
Huang J; Lai W; Wang Q; Tang Q; Hu C; Zhou M; Wang F; Xie D; Zhang Q; Liu W; Zhang Z; Zhang R
Int J Nanomedicine; 2021; 16():7497-7515. PubMed ID: 34803378
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
[TBL] [Abstract][Full Text] [Related]
3. iRGD mediated pH-responsive mesoporous silica enhances drug accumulation in tumors.
Wang X; Zhao Y; Yan M; Liang X; Zhao N; Lu T
Eur J Pharm Sci; 2024 Apr; 195():106725. PubMed ID: 38346565
[TBL] [Abstract][Full Text] [Related]
4. Multitargeted Nanoparticles Deliver Synergistic Drugs across the Blood-Brain Barrier to Brain Metastases of Triple Negative Breast Cancer Cells and Tumor-Associated Macrophages.
Zhang T; Lip H; He C; Cai P; Wang Z; Henderson JT; Rauth AM; Wu XY
Adv Healthc Mater; 2019 Sep; 8(18):e1900543. PubMed ID: 31348614
[TBL] [Abstract][Full Text] [Related]
5. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
6. Targeted polymeric nanoparticles for drug delivery to hypoxic, triple-negative breast tumors.
Mamnoon B; Loganathan J; Confeld MI; De Fonseka N; Feng L; Froberg J; Choi Y; Tuvin DM; Sathish V; Mallik S
ACS Appl Bio Mater; 2021 Feb; 4(2):1450-1460. PubMed ID: 33954285
[TBL] [Abstract][Full Text] [Related]
7. Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition.
Fan J; Liu B; Long Y; Wang Z; Tong C; Wang W; You P; Liu X
Acta Biomater; 2020 Sep; 113():554-569. PubMed ID: 32569637
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Effect of Doxorubicin-Chlorin E6-Loaded Mesoporous Silica Nanoparticles Combined with Ultrasound on Triple-Negative Breast Cancer.
Xu P; Yao J; Li Z; Wang M; Zhou L; Zhong G; Zheng Y; Li N; Zhai Z; Yang S; Wu Y; Zhang D; Dai Z
Int J Nanomedicine; 2020; 15():2659-2668. PubMed ID: 32368047
[TBL] [Abstract][Full Text] [Related]
9. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
[TBL] [Abstract][Full Text] [Related]
10. Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment.
Zhang Z; Qian H; Huang J; Sha H; Zhang H; Yu L; Liu B; Hua D; Qian X
Int J Nanomedicine; 2018; 13():4961-4975. PubMed ID: 30214200
[TBL] [Abstract][Full Text] [Related]
11. Erythrocyte-cancer Hybrid Membrane-camouflaged Mesoporous Silica Nanoparticles Loaded with Gboxin for Glioma-targeting Therapy.
Jiao X; Yu X; Gong C; Zhu H; Zhang B; Wang R; Yuan Y
Curr Pharm Biotechnol; 2022; 23(6):835-846. PubMed ID: 34825635
[TBL] [Abstract][Full Text] [Related]
12. Remarkable Boron Delivery Of iRGD-Modified Polymeric Nanoparticles For Boron Neutron Capture Therapy.
Chen J; Yang Q; Liu M; Lin M; Wang T; Zhang Z; Zhong X; Guo N; Lu Y; Xu J; Wang C; Han M; Wei Q
Int J Nanomedicine; 2019; 14():8161-8177. PubMed ID: 31632025
[TBL] [Abstract][Full Text] [Related]
13. Erythrocyte-cancer hybrid membrane-coated reduction-sensitive nanoparticles for enhancing chemotherapy efficacy in breast cancer.
Rezaei S; de Araújo Júnior RF; da Silva ILG; Schomann T; Eich C; Cruz LJ
Biomater Adv; 2023 Aug; 151():213456. PubMed ID: 37196459
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
16. A Novel Strategy through Combining iRGD Peptide with Tumor-Microenvironment-Responsive and Multistage Nanoparticles for Deep Tumor Penetration.
Cun X; Chen J; Ruan S; Zhang L; Wan J; He Q; Gao H
ACS Appl Mater Interfaces; 2015 Dec; 7(49):27458-66. PubMed ID: 26633260
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe
Fang Z; Li X; Xu Z; Du F; Wang W; Shi R; Gao D
Int J Nanomedicine; 2019; 14():5785-5797. PubMed ID: 31440047
[No Abstract] [Full Text] [Related]
18. Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound.
Deng Z; Xiao Y; Pan M; Li F; Duan W; Meng L; Liu X; Yan F; Zheng H
J Control Release; 2016 Dec; 243():333-341. PubMed ID: 27984104
[TBL] [Abstract][Full Text] [Related]
19. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
20. Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy.
Wei Y; Gao L; Wang L; Shi L; Wei E; Zhou B; Zhou L; Ge B
Drug Deliv; 2017 Nov; 24(1):681-691. PubMed ID: 28414557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
